Photodynamic Therapy Using HPPH in Treating Patients With Advanced Non-Small Cell Lung Cancer That Blocks the Air Passages

• Status: Terminated
• Trial end date: 2014-03-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Photodynamic therapy uses a drug, such as HPPH, that becomes active when it is exposed to a certain kind of light. When the drug is active, tumor cells are killed. This may be an effective treatment for advanced non-small cell lung cancer that blocks the air passages.

PURPOSE: This phase II trial is studying how well photodynamic therapy using HPPH works in treating patients with advanced non-small cell lung cancer that blocks the air passages.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Roswell Park Cancer Institute
• Collaborator: National Cancer Institute (NCI)

Criteria

DISEASE CHARACTERISTICS:

• Biopsy confirmed advanced obstructing endobronchial non-small cell lung cancer

• May have squamous cell carcinoma, adenocarcinoma, or large cell carcinoma histology

• Ineligible for or refused surgical resection

• Local endobronchial recurrence after prior surgical resection, radiotherapy, or chemotherapy allowed

• No evidence of tumor encasement of major pulmonary vessels on CT scan of the chest

PATIENT CHARACTERISTICS:

• Karnofsky performance status (PS) 50-100% OR ECOG PS 0-2

• WBC ≥ 4,000/mm³

• Platelet count ≥ 100,000/mm³

• Prothrombin time < 1.5 times upper limit of normal (ULN)

• Total bilirubin ≤ 2.0 mg/dL

• Creatinine ≤ 2.0 mg/dL

• Alkaline phosphatase (hepatic) ≤ 3 times ULN

• SGOT ≤ 3 times ULN

• No contraindications for bronchoscopy

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception during and for 3 months after the completion of study treatment

• Patients with underlying lung disease must be judged (by the principal investigator) able to withstand mucous/debris formation at the site of treatment

• Patients who cannot breathe due to complete upper airway obstruction and who need emergency treatment to open the airway are not eligible

• No porphyria or hypersensitivity to porphyrin or porphyrin-like compounds

• No severe chronic obstructive pulmonary disease that, in the opinion of the investigator, would preclude multiple bronchoscopies

• No partial central airway obstruction from mucous/debris formation

• No high-grade upper airway obstruction of the trachea

PRIOR CONCURRENT THERAPY:

• Any type of prior therapy (e.g., chemotherapy or radiotherapy) for lung cancer allowed

• At least 4 weeks since prior and no concurrent chemotherapy or radiotherapy